Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
CAPS Rating:
A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.
RSS Headlines
Fool UK
Recs
currently 100 shares in my portfolio.
I no longer update my portfolio positions.